Compare Quest Diagnostics Inc (DGX) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Wipro Limited — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while Wipro Limited trades at $1.69 (market cap $16.36B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Wipro Limited pays the higher dividend (5.19%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Wipro Limited for 41 Days on average.
| DGX | WIT | |
|---|---|---|
Market Cap | $25.06B | $16.36B |
Volume | 927,361 | 6,583,554 |
Sector | Health | Technology |
52-Week High | $247.45 | $3.06 |
52-Week Low | $173.49 | $1.61 |
Typical Hold Time | 56 Days | 41 Days |
Enterprise Value | $30.82B | $14.47B |
Dividend Yield | 1.52% | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
Wipro (WIT) trades at $1.67, down 0.6% with bearish technical signals despite recent AI productivity gains. The company reported $890.88B revenue for 2025 with solid 13.92% net margins and reasonable valuation (P/E 12.78). Recent quarters show earnings misses, but cash flow remains strong at $25.02B. Analyst sentiment is mixed with only 19% buy ratings.
Wipro faces execution risks amid competitive IT services market, though AI initiatives show promise. The stock offers value pricing but requires earnings acceleration to justify higher multiples. Near-term performance depends on client spending recovery and AI deployment success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
